Leutrol

• Anti-Inflammatory Agents, Non-Steroidal
• Leukotriene Antagonists
• Lipoxygenase Inhibitors

• Leutrol
• Zileuton [USAN:BAN:INN]
• Zileutonum [INN-Latin]
• Zyflo

• No information avaliable

C₁₁H₁₂N₂O₂S

http://www.rxlist.com/cgi/generic/zileuton.htm

Leutrol MSDS

No information avaliable

236.291 g/mol

144.2-145.2 ^oC

Practically insoluble (0.5 mg/ml)

Solid

1.437

Tablet (600mg)

For the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.

Zileuton is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway. Sulfido-peptide leukotrienes (LTC4, LTD4, LTE4, also known as the slow-releasing substances of anaphylaxis) and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid (BALF) from asthmatic patients. In humans, pretreatment with zileuton attenuated bronchoconstriction caused by cold air challenge in patients with asthma.

Rapidly and almost completely absorbed. The absolute bioavailability is unknown.

The oral minimum lethal doses in mice and rats were 500-4000 and 300-1000 mg/kg in various preparations, respectively (providing greater than 3 and 9 times the systemic exposure [AUC] achieved at the maximum recommended human daily oral dose, respectively).

Patients should be told that:

• ZYFLO is indicated for the chronic treatment of asthma and should be taken regularly as prescribed, even during symptom-free periods.
• ZYFLO is not a bronchodilator and should not be used to treat acute episodes of asthma.
• When taking ZYFLO, they should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
• While using ZYFLO, medical attention should be sought if short-acting bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed.
• The most serious side effect of ZYFLO is elevation of liver enzyme tests and that, while taking ZYFLO, they must return for liver enzyme test monitoring on a regular basis. If they experience signs and/or symptoms of liver dysfunction (e.g., right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or "flu-like" symptoms), they should contact their physician immediately.
• ZYFLO can interact with other drugs and that, while taking ZYFLO, they should consult their doctor before starting or stopping any prescription or non-prescription medicines.

A patient leaflet is included with the tablets.

Humans and other mammals